
|Videos|March 30, 2021
Examining TKI Combinations in Advanced RCC
A panel discusses the role of TKI combination therapies for patients with advanced renal cell carcinoma and how they have changed the treatment landscape.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer
2
Daraxonrasib Shows Antitumor Activity in RAS-Mutant NSCLC
3
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
4
G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC
5




























